Metraipolis › archive › dc_8a30508db15a
Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database — Europe PMC PMID:41788805
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41788805
- DOI
- 10.3389/fphar.2026.1765114
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T15:59:17.269Z
- SHA-256 of the archived text
b13b7d15f3b1035aaaaef114f65f42506339b6c9ff8165100e69ba55b703ad3f- Stable URL of this page
https://metraipolis.com/documento/dc_8a30508db15a
How to cite
Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database — Europe PMC PMID:41788805 — Europe PMC (en), https://europepmc.org/article/MED/41788805 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8a30508db15a (Metraipolis archive dc_8a30508db15a, sha256 b13b7d15f3b1035aaaaef114f65f42506339b6c9ff8165100e69ba55b703ad3f)
BibTeX
@misc{dc8a30508db15a,
title = {Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database — Europe PMC PMID:41788805},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41788805},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8a30508db15a; sha256 b13b7d15f3b1035aaaaef114f65f42506339b6c9ff8165100e69ba55b703ad3f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41788805. Agents can read the archived copy with the MCP tool read_document.